Medical device company InspireMD today announced positive results from a multi-center randomized trial of its MGuard™ embolic protection stent technology used for emergency treatment of patients suffering from heart attacks.
The company will present detailed results from the MASTER trial at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) meeting in Miami in October.
Ofir Paz, InspireMD's CEO, said the results signify a "key milestone" in the company's history; the company pointed out that stents for heart attack patients are expected to make up $1.8 billion of stent sales, or nearly 30 percent of the $5.9 billion global stent market.
The MASTER (MGuard forAcute ST Elevation Reperfusion) compared MGuard to commercially approved bare metal or drug-eluting stents. The trial enrolled 433 patients in nine countries.
The MGuard embolic protection stent is a coronary stent integrated with a proprietary micronet technology, which is designed to hold plaque and thrombus in place against the blocked artery's wall, thereby preventing debris from entering the bloodstream.
The company said that plans for a U.S. FDA registration trial are underway, and that it expects to commence patient enrollment by year end.
MGuard is already CE Mark approved.
For more information visit inspire-md.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net